🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

BMRN BMRN

Company Profile ↓
$59.91
-0.66% 1Y
P/E33.28
52W High$64.08
52W Low$49.67
EPS (TTM)$1.80

Company Overview

BMRN (BMRN) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 15.3% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 15.1% CAGR over the past five years.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $3.22B (+12.9% YoY); net profit $348.90M.
  • Trailing 12 Months Year-on-year growth — revenue +12.9%, earnings -18.3%.
  • 5-Year Trend Long-term compounding — revenue CAGR 15.1%, profit CAGR 15.3%.

Growth & Price Performance

Compounded Sales Growth

5 Years:15.06%
1 Year:12.87%

Compounded Profit Growth

5 Years:15.34%
1 Year:-18.26%

Stock Price Performance

1 Year:-0.66%
6 Months:+3.99%
3 Months:+12.53%
1 Month:-0.73%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 71% of range
$49.67 $64.08
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)53.51 · Neutral
Price Performance
1M-0.73%
3M+12.53%
6M+3.99%
1Y-0.66%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 15.1% over 5 years.
  • Profit CAGR of 15.3% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
33.28
Industry PE
-
Forward P/E est.
40.71
PEG Ratio
-
Book Value
$-
Price to Book
-
P/S
-
EV/EBITDA
-
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
15.06%
Profit 5Y
15.34%
Revenue (YoY)
12.87%
Earnings (YoY)
-18.26%

Profitability & Returns

ROCE
5.99%
ROE
5.73%
ROA
4.59%
Profit Margin
10.83%
Op Margin
12.71%
Gross Margin
-
EPS (Latest Qtr)
$0.54
EPS (TTM)
$1.80

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
-
Current Ratio
-
Debt
-
Total Assets
$8.59B
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
0.35%
Chg in Prom Hold
-
FII / Inst Holding
102.27%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
-
Total Revenue (TTM)
$3.22B
EBITDA
-
Free Cash Flow
$724.96M
Operating Cash Flow
$827.99M
Shares Outstanding
-
Gross Margin
-
Payout Ratio
-
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2013Mar 2014Jun 2014Sep 2014Mar 2015Jun 2015Sep 2015Mar 2016Jun 2016Sep 2016Mar 2017Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -----------317.45M334.15M373.45M372.85M391.71M400.75M387.76M461.10M502.07M429.49M476.78M486.03M501.69M408.74M519.36M533.80M505.34M596.41M595.27M581.33M648.83M712.03M745.74M-745.14M825.41M776.13M874.57M766.21M
Cost of Revenue -----------------------------------151.56M150.09M140.09M275.71M195.00M
Gross Profit -----------------------------------593.59M675.32M636.05M598.86M571.21M
Operating Expenses -----------------------------------369.68M398.45M682.73M643.46M441.58M
Operating Income -50.72M-26.46M-18.88M11.20M-65.86M-64.29M-81.87M-80.92M-572.81M-60.09M-20.21M-38.81M-13.73M-44.37M-25.26M-15.74M-53.95M-41.35M4.01M104.96M-40.95M-55.94M25.09M11.67M-53.22M137.33M39.15M-2.42M62.40M65.57M30.52M88.46M120.45M113.89M-223.91M276.87M-46.68M-44.60M129.63M
EBITDA -----------------------------------263.02M319.11M-5.26M-3.94M172.57M
Interest Expense -----------------------------------2.86M2.68M2.58M2.78M14.96M
Pretax Income -----------------------------------238.09M297.87M-26.32M-27.15M141.20M
Tax Provision -----------------------------------52.40M57.34M4.42M19.42M35.68M
Net Income -53.02M-38.12M-33.50M7.45M-67.50M-81.99M-90.93M-83.05M-419.01M-37.42M-16.29M-36.83M-12.53M-44.15M-16.79M-12.62M-56.47M-37.44M55.04M81.38M-29.18M784.80M17.37M12.94M-36.49M120.80M27.66M-6.65M50.85M56.04M40.38M88.66M107.17M106.08M-185.69M240.53M-30.74M-46.57M105.53M
Diluted EPS -0.38-0.27-0.230.05-0.43-0.51-0.60---0.22-0.09--0.07-0.26--0.07-0.32-0.210.300.44-0.164.010.090.07-0.200.630.15-0.040.270.290.210.460.550.55-0.951.23-0.16-0.240.54
R&D Expense 88.06M86.17M107.70M125.69M142.07M157.90M158.71M158.79M167.04M160.83M145.00M143.04M154.10M183.95M175.58M161.41M183.59M185.64M172.96M142.26M182.14M147.05M148.72M161.11M157.87M160.84M158.19M157.83M171.85M177.36M191.31M204.99M183.79M184.90M-158.73M161.31M409.48M-178.80M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 296.49M324.66M376.27M441.36M500.72M548.49M749.28M889.89M1.12B1.31B1.49B1.70B1.86B1.85B2.10B2.42B2.85B3.22B
Operating Income 39.76M16.43M544.00K-33.89M-110.22M-156.01M-92.89M-110.70M-803.43M-14.70M-123.52M-100.46M-43.44M-82.34M160.97M185.77M484.21M409.48M
Net Income 30.83M-488.00K205.82M-53.84M-114.35M-176.35M-133.97M-171.80M-630.21M-117.04M-77.21M-23.85M854.03M-64.08M141.56M167.65M426.86M348.90M
Diluted EPS 0.290.001.73-0.48-0.95--0.92-1.07-3.81-0.67-0.44-0.134.50-0.350.750.872.211.80
R&D Expense 93.29M115.12M147.31M214.37M302.22M354.78M461.54M634.81M661.90M610.75M696.33M715.01M628.12M628.79M649.61M746.77M747.18M921.93M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --917.16M1.26B1.31B1.57B2.24B2.48B3.73B4.02B4.63B4.43B4.69B5.85B6.00B6.38B6.84B6.99B7.59B
Total Equity 187.73M276.68M322.19M717.26M773.05M1.02B1.34B1.53B2.40B2.77B2.81B2.97B3.12B4.10B4.27B4.60B4.95B5.66B6.09B
Cash & Equivalents 228.34M222.90M167.17M88.08M46.27M180.53M568.78M875.49M397.04M408.33M598.03M493.98M437.45M649.16M587.28M724.53M755.13M942.84M1.31B
Total Liabilities --594.98M545.37M532.66M552.58M903.02M947.49M1.33B1.26B1.82B1.46B1.57B1.74B1.74B1.77B1.89B1.33B1.51B
Current Liabilities --78.15M83.84M94.12M170.43M183.27M235.74M445.46M439.31M816.52M523.24M932.50M492.55M546.50M588.88M1.18B606.99M759.03M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -9.18M87.73M18.75M18.41M17.61M-59.63M---227.84M-8.76M20.21M48.26M85.36M304.54M175.90M159.26M572.84M827.99M
Investing Cash Flow -19.08M-79.67M-101.34M-89.56M-195.65M-298.78M---484.05M-305.46M264.35M-31.03M-53.62M-366.31M-20.03M-111.24M136.49M-414.24M
Financing Cash Flow 22.81M-63.79M3.50M29.34M312.29M746.67M--727.11M507.14M-388.01M-74.67M181.12M-48.00K-18.65M-18.73M-526.45M-42.39M
Capital Expenditure -56.37M-89.80M-49.46M-73.22M-44.57M-65.19M-117.06M-227.65M-148.38M-199.22M-144.62M-145.03M-114.31M-95.58M-120.96M-96.69M-85.42M-103.04M
Free Cash Flow -65.54M-2.07M-30.71M-54.80M-26.96M-124.83M---376.22M-207.98M-124.41M-96.76M-28.95M208.96M54.94M62.57M487.42M724.96M
Share Buybacks ----------0050.00M00---

Ratios (Annual)

Figures in %.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ------------------
Operating Margin % 13.4%5.1%0.1%-7.7%-22.0%-28.4%-12.4%-12.4%-71.9%-1.1%-8.3%-5.9%-2.3%-4.5%7.7%7.7%17.0%12.7%
Net Margin % 10.4%-0.2%54.7%-12.2%-22.8%-32.2%-17.9%-19.3%-56.4%-8.9%-5.2%-1.4%45.9%-3.5%6.8%6.9%15.0%10.8%
ROE % 11.1%-0.2%28.7%-7.0%-11.3%-13.2%-8.8%-7.2%-22.8%-4.2%-2.6%-0.8%20.8%-1.5%3.1%3.4%7.5%5.7%
ROCE % -2.0%0.0%-2.8%-7.9%-7.6%-4.1%-3.4%-22.4%-0.4%-3.2%-2.7%-0.8%-1.5%2.8%3.3%7.6%6.0%

Shareholding Pattern

Insiders
0.35%
Institutions
102.27%
Public Float
102.63%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for BMRN

Google News Wed, 05 Aug 2026

BioMarin Pharmaceutical (BMRN) To Report Earnings Tomorrow: Here Is What To Expect - StockStory

<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxObUwzY0s0cE0ybHo4RWdzY2hBZXZCVjlZNEc3M3R1alBqREJLanNzM1RHMWFDc1dYUmRWdzRFMEVTamRJTzQ1anlzZ0FnNDk4VElSdTU2OTIwZ3pjUXNjNTd3czhLcHRVMEZJN1pEMEx3WHVHZFNub0FMc2dXM0UwbWEtQnRSQmN5d05JTF…

Google News Fri, 22 May 2026

Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxQcjdjXzROMG1yd2x2YUZDQjZFMmtjWmtCWVFUTURkSzFiQ01JZnA1b09TeXZoOHVNeTBMSDhscThaVTBhOERZY1FoamJpQ3p6bTNiazFEVGJhdGt3dElGVWxSaDdPVjBZUVo1R2JvTXVxSWhjUVhDSEtMcHpHLVdndVlfMU1PNS1vVkF2Wm…

Google News hu, 30 Jul 2026

BioMarin CEO to Give Business Update in Aug. 6 Webcast - Stock Titan

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxQUi1PdHNSZXFUWEVpVzg3cDJuWV9SbmUyb2V0WFltbUF0LTZvVlNJeUpWRzZrYzY4Q2ZJMEVHOWxiTU1DU0ZiNU9fUkxuVnEtcGtPZkFleXNZdVhKelRadkVlM2RvRU52Z2dtbjVlNkZzd09tOHBld3pCX0RIbkdqYmtjMERsNFhoTnpuYm…

Google News Mon, 27 Jul 2026

BioMarin Pharmaceutical (NASDAQ:BMRN): A Value Stock with Strong Fundamentals - ChartMill

<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxQSmlGSFNyUlEyMEw0aWlOWWIwZnJNd09SWG1LTHhTcXBvekxTZkZBOGRxXzZDMWZUbXdfaGhDbjFSZzBmanJsdEdXSGROVUNUakZFR3NXeFVfZ0c3cUNud3Q5dWNvSkhoVlFyZnNpcHdnMjYwYnY2ZWF0Y05NTHlXVnlZdkpvN0ZxaTFmYT…

Google News Mon, 04 May 2026

BioMarin Reports First Quarter 2026 Financial and Operating Results - PR Newswire

<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxQaE9PQVp2VzJjOWkza2VZZ25vUGRjY2UzVVkxNTFLeF9GTW1NUURkeXdNZmxIMURicnZZdklFYWtzdWJZQlotSkZMNE95YkdxY2NRb29NcGU2d0dwZ0MzWWhicEFiNnRDZldxZEZNdHdWSWxhQkR2N2dNd19VbzA0VTZTcDB1RGhBU0FESD…

Google News ue, 19 May 2026

BMRN Stock Down on Mixed Results From Rare Disease Therapy Study - Zacks Investment Research

<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxQM3NwbF82SmZFbXN1RVNtSk5hcld5ejVKZ2lmRjZZdnpfdTFHZFcxaFlHNWJDd0NGZnNKWUVGS2k4ZVVLeVR5LXFNSzlZYkRwYk13Y1R0MzFGcUg1dVotX3RMcDcxVU5tX3hYME82ODdkb1NaSXJKYjJ3S0tCLVZuWE5kbFBXR250cGk5Ml…

BMRN — Frequently Asked Questions

What is the current share price of BMRN?

As of 2026-08-05 17:25 PDT, BMRN trades at $59.91 on NASDAQ/NYSE. Its 52-week range is $49.67 to $64.08.

What is the P/E ratio of BMRN?

BMRN trades at a trailing price-to-earnings (P/E) ratio of 33.28.

What is the return on equity (ROE) of BMRN?

BMRN has a return on equity (ROE) of 5.73%. Its return on capital employed (ROCE) is 5.99%.

Is BMRN a good stock to buy?

This page provides a data-driven analysis of BMRN, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space